Immunome, Inc. logo IMNM - Immunome, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 12
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $36.20 DETAILS
HIGH: $40.00
LOW: $32.00
MEDIAN: $36.00
CONSENSUS: $36.20
UPSIDE: 67.13%

Stock News

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

Immunome Reports First Quarter 2026 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the quarter ended March 31, 2026, and provided a business update. “This quarter reflects the progress we are making in building Immunome into a multi-program targeted oncology company,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Immunome. “The NDA submission for v.

May 12, 2026 12:02 PM • businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on May 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 450,000 shares of common stock to nineteen new employees under the Company's 2024 Indu.

May 05, 2026 12:00 PM • businesswire.com
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor (GSI), for the treatment of adults with desmoid tumors. “The varegacestat NDA submission marks an important milestone for Immunome. It r.

Apr 29, 2026 03:30 AM • businesswire.com
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its global, Phase 3, randomized, placebo-controlled trial of varegacestat in patients with progressing desmoid tumors, has been selected for presentation in an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 2.

Apr 21, 2026 06:30 AM • businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 188,500 shares of common stock to thirteen new employees under the Company's 2024 In.

Apr 02, 2026 12:00 PM • businesswire.com
Immunome: Upcoming NDA, Valuation, And Investment Case

Immunome: Upcoming NDA, Valuation, And Investment Case

Immunome is advancing varegacestat for desmoid tumors, targeting NDA submission in Q2 2026 after positive phase 3 RINGSIDE data. Varegacestat demonstrated superior efficacy and safety versus nirogacestat, with an 84% risk reduction in progression or death and a 56% objective response rate. Despite a small addressable market (~3,000 patients), conservative peak global sales are estimated at $280 million, supporting a valuation over 235% above IMNM's current market cap.

Mar 10, 2026 08:51 PM • seekingalpha.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on March 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 282,000 shares of common stock to seven new employees under the Company's 2024 Induc.

Mar 05, 2026 11:00 AM • businesswire.com
Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing

Sold all 3,185,000 shares of Immunome, estimated at $37.30 million based on quarterly average pricing Quarter-end position value decreased by $37.30 million, reflecting both stock price movement and the sale Represents a 4.92% decrease in Opaleye Management's 13F reportable assets under management Post-trade, Opaleye Management holds zero shares and zero dollar value in Immunome The position accounted for 5.3% of fund AUM in the prior quarter, marking a significant shift in portfolio composition

Mar 04, 2026 07:12 AM • fool.com
Immunome Reports Full Year 2025 Financial Results and Provides Business Update

Immunome Reports Full Year 2025 Financial Results and Provides Business Update

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial results for the full year ended December 31, 2025, and provided a business update. “Immunome made substantial progress in 2025. The positive Phase 3 RINGSIDE results represent a significant milestone for patients living with desmoid tumors and will support our planned NDA submission for varegacestat in.

Mar 03, 2026 11:02 AM • businesswire.com
Immunome to Present at Upcoming Investor Conferences

Immunome to Present at Upcoming Investor Conferences

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members of Immunome's management will present at the following investor conferences: TD Cowen 46th Annual Health Care Conference Presentation Date/Time: March 3, 2026, at 9:50 a.m. ET Leerink Partners Global Healthcare Conference Presentation Date/Time: March 10, 2026, at 3 p.m. ET Interested parties can ac.

Feb 23, 2026 03:00 AM • businesswire.com
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on February 2, 2026, the Compensation Committee of the Company's Board of Directors (the “Compensation Committee”) granted inducement awards consisting of non-statutory stock options to purchase an aggregate of 30,000 shares of common stock to one new employee under the Company's 2024 Induce.

Feb 05, 2026 11:00 AM • businesswire.com

Price Targets